Literature DB >> 21989746

Pericarditis and pericardial effusion: management update.

Dina M Sparano1, R Parker Ward.   

Abstract

OPINION STATEMENT: Prompt recognition of the signs and symptoms of pericardial disease is critical so that appropriate treatments can be initiated. Acute pericarditis has a classical presentation, including symptoms, physical examination findings, and electrocardiography abnormalities. Early recognition of acute pericarditis will avoid unnecessary invasive testing and prompt therapies that provide rapid symptom relief. Non-steroidal anti-inflammatory drugs (NSAIDs) remain first-line therapy for uncomplicated acute pericarditis, although colchicine can be used concomitantly with NSAIDS as the first-line approach, particularly in severely symptomatic cases. Colchicine should be used in all refractory cases and as initial therapy in all recurrences. Aspirin should replace NSAIDS in pericarditis complicating acute myocardial infarction. Systemic corticosteroids can be used in refractory cases or in those with immune-mediated etiologies, although generally should be avoided due to a higher risk of recurrence. Pericardial effusions have many etiologies and the approach to diagnosis and therapy depends on clinical presentation. Pericardial tamponade is a life-threatening clinical diagnosis made on physical examination and supported by characteristic findings on diagnostic testing. Prompt diagnosis and management is critical. Treatment consists of urgent pericardial fluid drainage with a pericardial drain left in place for several days to help prevent acute recurrence. Analysis of pericardial fluid should be performed in all cases as it may provide clues to etiology. Consultation of cardiac surgery for pericardial window should be considered in recurrent cases and may be the first-line approach to malignant effusions, although acute relief of hemodynamic compromise must not be delayed. Constrictive pericarditis is associated with symptoms that mimic many other cardiac conditions. Thus, correct diagnosis is critical and involves identification of pericardial thickening or calcification in association with characteristic hemodynamic alterations using noninvasive and invasive diagnostic approaches. Constrictive physiology may occur transiently and resolve with medical therapy. In chronic cases, definitive therapy requires referral to an experienced surgeon for pericardiectomy.

Entities:  

Year:  2011        PMID: 21989746     DOI: 10.1007/s11936-011-0151-8

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  28 in total

Review 1.  Medical therapy of pericardial diseases: part II: Noninfectious pericarditis, pericardial effusion and constrictive pericarditis.

Authors:  Massimo Imazio; Antonio Brucato; Bongani M Mayosi; Francesco Giuseppe Derosa; Chiara Lestuzzi; Antonio Macor; Rita Trinchero; David H Spodick; Yehuda Adler
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2010-11       Impact factor: 2.160

Review 2.  Congenital absence of pericardium revisited.

Authors:  Yang Faridah; Paul R Julsrud
Journal:  Int J Cardiovasc Imaging       Date:  2002-02       Impact factor: 2.357

3.  Risk prediction in pericarditis: who to keep in hospital?

Authors:  David H Spodick
Journal:  Heart       Date:  2008-04       Impact factor: 5.994

Review 4.  Multimodality imaging of pericardial diseases.

Authors:  Kibar Yared; Aaron L Baggish; Michael H Picard; Udo Hoffmann; Judy Hung
Journal:  JACC Cardiovasc Imaging       Date:  2010-06

5.  Neoplastic pericardial disease: Old and current strategies for diagnosis and management.

Authors:  Chiara Lestuzzi
Journal:  World J Cardiol       Date:  2010-09-26

6.  Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade.

Authors:  G Liu; M Crump; P E Goss; J Dancey; F A Shepherd
Journal:  J Clin Oncol       Date:  1996-12       Impact factor: 44.544

7.  Subxiphoid pericardial drainage for pericardial tamponade.

Authors:  D W Moores; K B Allen; L P Faber; S W Dziuban; D J Gillman; W H Warren; R Ilves; L Lininger
Journal:  J Thorac Cardiovasc Surg       Date:  1995-03       Impact factor: 5.209

8.  Constrictive pericarditis in the modern era: novel criteria for diagnosis in the cardiac catheterization laboratory.

Authors:  Deepak R Talreja; Rick A Nishimura; Jae K Oh; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2008-01-22       Impact factor: 24.094

9.  Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial.

Authors:  Riichiroh Maruyama; Hideki Yokoyama; Takashi Seto; Seiji Nagashima; Kosuke Kashiwabara; Jun Araki; Hiroshi Semba; Yukito Ichinose
Journal:  J Thorac Oncol       Date:  2007-01       Impact factor: 15.609

10.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

Authors:  H Kunitoh; T Tamura; T Shibata; M Imai; Y Nishiwaki; M Nishio; A Yokoyama; K Watanabe; K Noda; N Saijo
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

View more
  3 in total

1.  A novel prognostic marker in acute ischemic stroke: small pericardial effusion.

Authors:  Murat Biteker; Ahmet Ilker Tekkeşin; Akın Dayan; Cemile Handan Mısırlı
Journal:  J Neurol       Date:  2012-04-19       Impact factor: 4.849

2.  Abnormal echocardiography 7 days after stem cell transplantation may be an early indicator of thrombotic microangiopathy.

Authors:  Christopher E Dandoy; Stella M Davies; Russel Hirsch; Ranjit S Chima; Zachary Paff; Michelle Cash; Thomas D Ryan; Adam Lane; Javier El-Bietar; Kasiani C Myers; Sonata Jodele
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-06       Impact factor: 5.742

3.  Hemoglobin-associated oxidative stress in the pericardial compartment of postoperative cardiac surgery patients.

Authors:  Philip A Kramer; Balu K Chacko; Saranya Ravi; Michelle S Johnson; Tanecia Mitchell; Stephen Barnes; Alireza Arabshahi; Louis J Dell'Italia; David J George; Chad Steele; James F George; Victor M Darley-Usmar; Spencer J Melby
Journal:  Lab Invest       Date:  2014-12-01       Impact factor: 5.662

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.